MAS
ALNY icon

Meeder Advisory Services’s Alnylam Pharmaceuticals ALNY Stock Holding History

Meeder Advisory Services’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$485K Sell
1,611
-242
-13% -$73K 0.02% 439
2026
Q1 		$613K Buy
1,853
+15
+0.8% +$5.1K 0.03% 359
2025
Q4 		$731K Sell
1,838
-51
-3% -$22.6K 0.03% 331
2025
Q3 		$861K Buy
1,889
+764
+68% +$311K 0.04% 295
2025
Q2 		$367K Buy
1,125
+147
+15% +$40.7K 0.02% 440
2025
Q1 		$264K Buy
978
+72
+8% +$18.5K 0.02% 483
2024
Q4 		$213K Sell
906
-27
-3% -$7.1K 0.01% 525
2024
Q3 		$257K Buy
+933
New +$243K 0.02% 473

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Meeder Advisory Services's ALNY Position: Q2 2026 in Review

Meeder Advisory Services reduced its Alnylam Pharmaceuticals (ALNY) stake by 13% in Q2 2026, selling an estimated $73K and leaving 1,611 shares worth $485K. The position accounts for 0.02% of the portfolio, ranked #439.

Meeder Advisory Services first reported a position in ALNY in Q3 2024 and has held it in 8 quarters since. The position peaked at $861K in Q3 2025. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Meeder Advisory Services held 1,611 shares of Alnylam Pharmaceuticals worth $485K as of Q2 2026.
  • Meeder Advisory Services sold 242 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $73K.
  • Alnylam Pharmaceuticals made up 0.02% of Meeder Advisory Services's portfolio in Q2 2026, its #439 holding.
  • Meeder Advisory Services first reported a position in Alnylam Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
  • Meeder Advisory Services's Alnylam Pharmaceuticals position peaked at $861K in Q3 2025.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Meeder Advisory Services's 13F filing for Q2 2026, filed 7 Aug 2026.